FDA Approves First At-Home Subcutaneous Treatment for Thyroid Eye Disease
Summary
The FDA approved Genentech's Enspryng (satralizumab) for thyroid eye disease, making it the first and only at-home subcutaneous option for the condition. This is the second indication for Enspryng after its 2020 NMOSD approval and follows a priority review. The pivotal SatraGO-2 trial showed a 52.9% proptosis response versus 23.4% for placebo and a 60.7% diplopia reduction versus 25.8%, though SatraGO-1 missed its primary endpoint at week 24. The approval adds a new revenue stream in a rare disease affecting roughly 155 per 100,000 people, where existing therapies are infusion-based. An FDA decision on Enspryng for MOGAD is expected in January 2027.
At the time of this announcement, RHHBY was trading at $56.78 on OTC in the Life Sciences sector, with a market capitalization of approximately $354.3B. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: BusinessWire.